All In Biotech

Drug Trial Radar · NCT06184659

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial

Last checked: Nov 19, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 5,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,800

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Jun 30, 2028

Study completion Mar 30, 2029

Sponsor

Lead sponsor
Scandinavian Critical Care Trials GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

Conditions

  • Sepsis
  • Septic Shock

Interventions

  • MeropenemDrug

    For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion

  • Piperacillin/TazobactamDrug

    Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: Baseline to 30 days after enrollment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Rigshospitalet

    Copenhagen, København Ø, Denmark · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.